Clinical Trials in Klagenfurt, Austria
36 recruiting
Showing 1–20 of 38 trials
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled380 locationsNCT05920356
Recruiting
Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Chronic Migraine
Merz Therapeutics GmbH780 enrolled106 locationsNCT07018713
Recruiting
Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Episodic Migraine
Merz Therapeutics GmbH990 enrolled106 locationsNCT07018700
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled596 locationsNCT07037459
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Not Applicable
Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome
Myofascial Pain Syndrome - Lower BackMyofascial Pain Syndrome - NeckMyofascial Pain Syndrome - Tension Headache
Sobet AG126 enrolled6 locationsNCT05851326
Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
Cancer
EMD Serono Research & Development Institute, Inc.700 enrolled64 locationsNCT05376891
Recruiting
Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC15,000 enrolled880 locationsNCT05702034
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Janssen Research & Development, LLC380 enrolled48 locationsNCT07230691
Recruiting
Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline960 enrolled159 locationsNCT06961214
Recruiting
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Primary Hypercholesterolemiia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,000 enrolled163 locationsNCT06686615
Recruiting
Not Applicable
Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation
Myocardial InfarctionSudden Cardiac Death
Charite University, Berlin, Germany3,595 enrolled86 locationsNCT05665608
Recruiting
Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Community-acquired Pneumonia
Biotest590 enrolled147 locationsNCT05722938
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Breast Neoplasms
Novartis Pharmaceuticals3,250 enrolled274 locationsNCT06830720
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 3
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398
Recruiting
Phase 3
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Alpha1-Antitrypsin Deficiency
Takeda160 enrolled89 locationsNCT05677971
Recruiting
Phase 3
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Alpha1-Antitrypsin Deficiency
Takeda50 enrolled41 locationsNCT06165341
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732